Trials / Completed
CompletedNCT05702450
Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310
A Randomized, Open, Parallel Phase I Clinical Study on the Comparison of Pharmacokinetics Characteristics of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.
Detailed description
This study includes screening and treatment and follow-up periods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | CM310 Recombinant Humanized Monoclonal Antibody Injection |
Timeline
- Start date
- 2023-03-22
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
- First posted
- 2023-01-27
- Last updated
- 2024-10-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05702450. Inclusion in this directory is not an endorsement.